Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Operating Expenses: 2020-2024

Historic Operating Expenses for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Dec 2024 value amounting to $303.5 million.

  • Tarsus Pharmaceuticals' Operating Expenses rose 81.80% to $133.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $453.5 million, marking a year-over-year increase of 67.83%. This contributed to the annual value of $303.5 million for FY2024, which is 88.99% up from last year.
  • Tarsus Pharmaceuticals' Operating Expenses amounted to $303.5 million in FY2024, which was up 88.99% from $160.6 million recorded in FY2023.
  • Tarsus Pharmaceuticals' 5-year Operating Expenses high stood at $303.5 million for FY2024, and its period low was $27.0 million during FY2020.
  • Its 3-year average for Operating Expenses is $184.2 million, with a median of $160.6 million in 2023.
  • Data for Tarsus Pharmaceuticals' Operating Expenses shows a peak YoY spiked of 156.26% (in 2021) over the last 5 years.
  • Over the past 5 years, Tarsus Pharmaceuticals' Operating Expenses (Yearly) stood at $27.0 million in 2020, then spiked by 156.26% to $69.2 million in 2021, then increased by 27.96% to $88.5 million in 2022, then soared by 81.42% to $160.6 million in 2023, then surged by 88.99% to $303.5 million in 2024.